GB1352415A - Esters of substituted nicotine acids - Google Patents

Esters of substituted nicotine acids

Info

Publication number
GB1352415A
GB1352415A GB1249771A GB1249771A GB1352415A GB 1352415 A GB1352415 A GB 1352415A GB 1249771 A GB1249771 A GB 1249771A GB 1249771 A GB1249771 A GB 1249771A GB 1352415 A GB1352415 A GB 1352415A
Authority
GB
United Kingdom
Prior art keywords
dimethylamino
morpholino
piperidino
pyrrolidinyl
piperazinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB1249771A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boots Co PLC
Original Assignee
Boots Co PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR7016801A external-priority patent/FR2088018A1/en
Priority claimed from FR7016802A external-priority patent/FR2088019A1/en
Application filed by Boots Co PLC filed Critical Boots Co PLC
Publication of GB1352415A publication Critical patent/GB1352415A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

1352415 Substituted nicotinic acid esters BOOTS CO Ltd 30 April 1971 [8 May 1970 (2)] 12497/71 Heading C2C Novel nicotinic acid esters of formulae and pharmaceutically acceptable salts thereof wherein (a) A 1 is ethylene and R 1 is dimethylamino, 1-pyrrolidinyl, piperidino or 4-methyl-1-piperazinyl or A 1 is propylene and R 1 is dimethylamino, diethylamino, 1-pyrrolidinyl, piperidino or morpholino; (b) A 2 is ethylene and R 2 is diethylamino, 1-pyrrolidinyl, morpholino or 4-methyl-1-piperazinyl or A 2 is propylene and R 2 is dimethylamino, morpholino or 4-methyl-1-piperazinyl; (c) A 3 is ethylene and R 3 is dimethylamino, piperidino or morpholino or A 3 is propylene and R 3 is dimethylamino or 4-methyl-1-piperazinyl ; and (d) A 4 is ethylene and R 4 is dimethylamino or A 4 is propylene and R 4 is diethylamino, 1- pyrrolidinyl, piperidino or morpholino, are prepared from the required amino-alcohols by transesterification or by reaction with the required carboxylic acid or acid chloride. Pharmaceutical compositions having vasomotor activities and which may be in a form for oral, rectal or parenteral administration contain the above novel nicotinic acid esters or salts thereof as the active ingredients. The composition may be in the form of tablets, capsules, syrups, aqueous or oily suspensions or suppositories.
GB1249771A 1970-05-03 1971-04-30 Esters of substituted nicotine acids Expired GB1352415A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7016801A FR2088018A1 (en) 1970-05-03 1970-05-03 Vasodilatory, substd nicotinic acid amino ester derivs
FR7016802A FR2088019A1 (en) 1970-05-08 1970-05-08 Esters of 2 and 6-substituted nicotinic acids - with vasomotor active

Publications (1)

Publication Number Publication Date
GB1352415A true GB1352415A (en) 1974-05-08

Family

ID=26215726

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1249771A Expired GB1352415A (en) 1970-05-03 1971-04-30 Esters of substituted nicotine acids

Country Status (3)

Country Link
BE (1) BE766808A (en)
ES (1) ES390924A1 (en)
GB (1) GB1352415A (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524957B2 (en) 2001-08-17 2009-04-28 Astrazeneca Ab Compounds effecting glucokinase
US7642263B2 (en) 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7671060B2 (en) 2006-10-26 2010-03-02 Astrazeneca Ab Heteroaryl benzamide derivatives
US7696191B2 (en) 2006-12-21 2010-04-13 Astrazeneca Ab Crystalline compound
US7700640B2 (en) 2004-10-16 2010-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
US7709505B2 (en) 2002-11-19 2010-05-04 Astrazeneca Ab Benzofuran derivatives, process for their preparation and intermediates thereof
US7745475B2 (en) 2004-06-05 2010-06-29 Astrazeneca Ab Heteroaryl benzamide derivatives as GLK activators
US7902200B2 (en) 2006-10-23 2011-03-08 Astrazeneca Ab Chemical compounds
US7943607B2 (en) 2005-05-27 2011-05-17 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7973178B2 (en) 2005-11-28 2011-07-05 Astrazeneca Ab Chemical process for the preparation of an amido-phenoxybenzoic acid compound
US8071608B2 (en) * 2009-04-09 2011-12-06 Astrazeneca Ab Therapeutic agents
US8071585B2 (en) 2009-04-09 2011-12-06 Astrazeneca Ab Therapeutic agents
US8076481B2 (en) 2009-02-13 2011-12-13 Astrazeneca Ab Chemical process 632
US8093252B2 (en) 2009-02-13 2012-01-10 Astrazeneca Ab Crystalline polymorphic form of glucokinase activator
US8143263B2 (en) 2008-08-04 2012-03-27 Astrazeneca Ab Therapeutic agents

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951830B2 (en) 2001-08-17 2011-05-31 Astrazeneca Ab Compounds effecting glucokinase
US7524957B2 (en) 2001-08-17 2009-04-28 Astrazeneca Ab Compounds effecting glucokinase
US7709505B2 (en) 2002-11-19 2010-05-04 Astrazeneca Ab Benzofuran derivatives, process for their preparation and intermediates thereof
US7745475B2 (en) 2004-06-05 2010-06-29 Astrazeneca Ab Heteroaryl benzamide derivatives as GLK activators
US7700640B2 (en) 2004-10-16 2010-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
US7943607B2 (en) 2005-05-27 2011-05-17 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7977328B2 (en) 2005-07-09 2011-07-12 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7842694B2 (en) 2005-07-09 2010-11-30 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7642259B2 (en) 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7642263B2 (en) 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7973178B2 (en) 2005-11-28 2011-07-05 Astrazeneca Ab Chemical process for the preparation of an amido-phenoxybenzoic acid compound
US7902200B2 (en) 2006-10-23 2011-03-08 Astrazeneca Ab Chemical compounds
US7964725B2 (en) 2006-10-26 2011-06-21 Astrazeneca Ab Heteroarylbenzamide derivatives for use in the treatment of diabetes
US7671060B2 (en) 2006-10-26 2010-03-02 Astrazeneca Ab Heteroaryl benzamide derivatives
US7696191B2 (en) 2006-12-21 2010-04-13 Astrazeneca Ab Crystalline compound
US8143263B2 (en) 2008-08-04 2012-03-27 Astrazeneca Ab Therapeutic agents
US8076481B2 (en) 2009-02-13 2011-12-13 Astrazeneca Ab Chemical process 632
US8093252B2 (en) 2009-02-13 2012-01-10 Astrazeneca Ab Crystalline polymorphic form of glucokinase activator
US8071608B2 (en) * 2009-04-09 2011-12-06 Astrazeneca Ab Therapeutic agents
US8071585B2 (en) 2009-04-09 2011-12-06 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
BE766808A (en) 1971-11-08
ES390924A1 (en) 1974-04-01

Similar Documents

Publication Publication Date Title
GB1352415A (en) Esters of substituted nicotine acids
GB1250538A (en)
GB1181673A (en) Derivatives of Xanthen and Thiaxanthen and Preparation Thereof
GB1374367A (en) Propionamide derivative a method of making it and therapeutic compositions containing it
GB1355147A (en) Oxoprostanoic acid derivatives
DK535484A (en) CYCLOHEXANDERIVATIVES, PROCEDURES FOR PREPARING IT, AND PHARMACEUTICAL PRODUCTS WITH CONTENTS
GB1348089A (en) 1-oxa-3,8diaza spiro-4,5-decane derivatives and processes for preparing them
GB1225462A (en)
GB1261989A (en) 5-thiazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing the same
GB1424432A (en) Pharmaceutical compositions
GB1164360A (en) A process for Preparing Tricyclic Organic Compounds
GB1175617A (en) Substituted Pteridine Derivatives
IE32859L (en) Penicilloic acid derivatives.
GB1175907A (en) Substituted Pteridine Derivatives
GB1139146A (en) Benzofuran derivatives and processes for preparing the same
GB1423761A (en) Xylidides
GB1317236A (en) Preparation of 2-aryl-as-triazine-3,5,2h,4h-diones
GB1264197A (en)
GB1187733A (en) 0,3,10-Berbine Derivatives, their Acid Addition Salts, and Process for the Preparation Thereof
GB1207116A (en) Morphanthridine derivatives
GB1177957A (en) Production of Oxazepines and Thiazepines
ES382616A1 (en) 4-(thieno[2,3-b][1,5]benzothiazepin-4-yl)-piperazinyl-alkyl-3-alkyl-2-imidazolidinones as cns-depressants
GB1417822A (en) 4,8-dimethoxy-furo 3,2-f- benzoxazol-2-yl acethydroxamic acid its process of preparation and its therapeutic preparation
GB1429923A (en) Isoxazole derivatives and the production thereof
GB1190680A (en) Halocinnamoyl Piperidines and Morpholines and Pharmaceutical Compositions Containing Them

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee